# Link Cell Therapies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/link-cell-therapies

- Industry: Biotechnology
- Headquarters: San Carlos, US
- Website: www.linkcelltx.com/
- Total disclosed funding: $102M
- Latest round: Series A (Sep 28, 2026)
- Investors on record: 9

## About

Link Cell Therapies, Inc is a biotechnology company specializing in innovative cancer treatments, established in 2022 in South San Francisco, US. The company was co-founded by Robbie Majzner, M.D., Crystal Mackall, M.D., and Brian Slingerland. In September 2026, Link Cell Therapies, Inc raised USD 30 million in series A funding. The round was a part of a larger USD 90 million series A funding led by Johnson & Johnson Innovation, with participation from Bristol-Myers Squibb Company, Kyowa Kirin, Samsara BioCapital, Sheatree Capital, Wing, Western Technology Investment, Sherpa Healthcare Partners, and Cancer Focus Fund.
Link Cell Therapies specializes in innovative cancer cell therapies, focusing on developing CAR T agents designed for solid tumors. Their core product offerings revolve around a proprietary AND-gate CAR T technology that enhances specificity and safety compared to existing therapies by requiring simultaneous expression of cancer targets to activate cell cytotoxicity. This technology aims to address significant challenges in treating solid tumors and certain hematologic cancers, with potential applications in pediatric oncology. Their therapeutic programs target healthcare providers and oncologists across North America, Europe, and Asia, where advanced cancer treatments are in high demand.
Link Cell Therapies generates revenue through partnerships and collaborations with biotechnology firms and healthcare institutions involved in cancer treatment and research. Their revenue model typically involves joint ventures or licensing agreements for the development and commercialization of their CAR T therapies. Collaborations with pharmaceutical companies integrate their technologies into existing treatment pipelines, which may include milestone payments and royalties based on sales of approved therapies. Their unique AND-gate CAR T technology is expected to attract investment from healthcare providers and biotechnology firms, linking revenue generation to successful clinical trials and product approvals.
The company will use the September funding to support clinical and preclinical development of additional logic-gated CAR-T programs, advance its colorectal cancer program toward a first-in-human trial, and expand its pipeline through internal development and partnerships.

## Funding rounds

- Series A, Sep 28, 2026, $30M — Western Technology Investment, Johnson & Johnson Innovation, Wing, Bristol-Myers Squibb Company, Samsara BioCapital, Sherpa Healthcare Partners, Kyowa Kirin, Cancer Focus Fund, Sheatree Capital
- Series A, Dec 15, 2025, $60M — Johnson & Johnson Innovation, Bristol-Myers Squibb Company, Wing, Samsara BioCapital, Kyowa Kirin, Sheatree Capital
- Seed, May 1, 2022, $12M — Samsara BioCapital, Sheatree Capital

## Investors

- Samsara BioCapital (https://capitalatlas.ai/funds/samsara-biocapital) — Seed, Series A
- Sheatree Capital — Seed, Series A
- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series A
- Bristol-Myers Squibb Company — Series A
- Wing (https://capitalatlas.ai/funds/wing) — Series A
- Kyowa Kirin — Series A
- Western Technology Investment (https://capitalatlas.ai/funds/western-technology-investment) — Series A
- Sherpa Healthcare Partners (https://capitalatlas.ai/funds/sherpa-healthcare-partners) — Series A
- Cancer Focus Fund (https://capitalatlas.ai/funds/cancer-focus-fund) — Series A